GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Up 368.1% in July

GlucoTrack, Inc. (NASDAQ:GCTK) saw a large growth in short interest in July. As of July 15th, there was short interest totaling 2,388,682 shares, a growth of 368.1% from the June 30th total of 510,338 shares. Based on an average daily trading volume, of 11,948,792 shares, the short-interest ratio is presently 0.2 days. Currently, 31.7% of the company’s stock are sold short.

GlucoTrack Stock Performance

GCTK traded down $0.02 on Friday, reaching $0.29. 273,849 shares of the stock were exchanged, compared to its average volume of 8,697,584. The company’s 50-day moving average price is $0.45 and its 200 day moving average price is $1.24. GlucoTrack has a fifty-two week low of $0.29 and a fifty-two week high of $14.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.85 and a quick ratio of 0.85. The firm has a market capitalization of $2.25 million, a PE ratio of -0.02 and a beta of 0.77.

Analyst Upgrades and Downgrades

GCTK has been the subject of a number of research analyst reports. Wall Street Zen cut GlucoTrack to a “strong sell” rating in a research note on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On GlucoTrack

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE boosted its position in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after buying an additional 4,085 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in GlucoTrack during the 4th quarter worth approximately $52,000. Finally, Ikarian Capital LLC acquired a new stake in GlucoTrack during the 4th quarter valued at approximately $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.